sons. This assignment is based on two studies in Chinese benzidine production and use facilities. But it contrasts with results obtained in Caucasian populations, where slow acetylators, when exposed to aromatic amines, are at the higher risk (3) .
On the basis of their study, the authors concluded that the NAT2 genotype had no impact on bladder cancer risk. In Europe, the production of most carcinogenic aromatic amines, such as benzidine, was stopped in the 1960s and early 1970s, mostly due to legal regulations. From 1991 to 1993, we conducted a hospital-based study in the county of Leverkusen, a hotspot area of human bladder cancer and of former manufacture of carcinogenic aromatic amines (4). Of note, 55% of the 196 phenotyped bladder cancer patients comprised slow acetylators at a normal percentage (55%). However, the portion of slow acetylators was higher (62%-71%) in subgroups with specific histories of occupational exposure.
It also seems that the "slow" NAT2 genotypes comprise combinations of different "slow" haplotypes with different resulting metabolizing capacities. In this context, we could recently show that the frequent "ultraslow" NAT2 Ã 6A was associated with an elevated bladder cancer risk, based on 1,712 bladder cancer cases and 2,020 controls (5).
In essence, we regard the final statement of the authors (1) that "testing for NAT2 would be inappropriate in occupational settings" as an overinterpretation. 
